Answers are grounded in this paper and cite their sources.
Preclinical study reveals enhanced cellular uptake and stability of l-homoarginine peptides in cancer cells, highlighting potential for targeted boron delivery.
The use of cell-penetrating peptides (CPPs) for the intracellular delivery of pharmaceuticals has progressed from basic research to global clinical studies. In this study, we investigated the effects of introducing l-homoarginine into the CPP oligoarginine on intracellular uptake and membrane permeability efficiency. We demonstrated that extending the arginine side chain by one methylene group (l-homoarginine) significantly increased the intracellular uptake of hexa-oligoarginine compared with extension of the main chain by one carbon atom (l-β-homoarginine). Incorporation of the l-homoarginine sequence improved the short-term stability of hexa-oligoarginine in fetal bovine serum. Furthermore, this strategy showed potential utility in boron neutron capture therapy; when used as an intracellular delivery vehicle, the l-homoarginine-containing peptide facilitated the intracellular delivery of therapeutic boron-containing agents and the effects of thermal neutron irradiation, resulting in increased cancer cell killing. These findings demonstrate that the introduction of l-homoarginine residues is an effective approach for improving the intracellular delivery efficiency and biological stability of CPPs.
No takes yet. Share an insight, caveat, or question.
Taniyama et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: